世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

世界と日本のNSCLC向け標的薬剤BRAF阻害剤の市場規模、現状、予測2021-2027年


Global and Japan Targeted Drug BRAF Inhibitors for NSCLC Market Size, Status and Forecast 2021-2027

市場分析と洞察。世界のNSCLC向け標的薬剤BRAF阻害剤市場 世界のNSCLC向け標的薬剤BRAF阻害剤の市場規模は、2020年のXX百万米ドルから2021-2027年の間にXX%のCAGRで推移し、2027年にはXX百万米ドルに達すると予... もっと見る

 

 

出版社 出版年月 電子版価格 言語
QYResearch
QYリサーチ
2021年11月5日 US$3,900
シングルユーザライセンス
ライセンス・価格情報
注文方法はこちら
英語

※当ページの内容はウェブ更新時の情報です。
最新版の価格やページ数などの情報についてはお問合せください。

日本語のページは自動翻訳を利用し作成しています。
実際のレポートは英文のみでご納品いたします。


 

サマリー

市場分析と洞察。世界のNSCLC向け標的薬剤BRAF阻害剤市場
世界のNSCLC向け標的薬剤BRAF阻害剤の市場規模は、2020年のXX百万米ドルから2021-2027年の間にXX%のCAGRで推移し、2027年にはXX百万米ドルに達すると予測されています。
本レポートは、業界標準の正確な分析と高いデータの整合性により、世界のNSCLC向け標的薬剤BRAF阻害剤市場で得られる主要な機会を明らかにし、プレイヤーが市場での強力なポジションを獲得するのに役立つ見事な試みを行っています。本レポートの購入者は、検証された信頼性の高い市場予測にアクセスすることができます。その中には、収益面での世界的なTargeted Drug BRAF Inhibitors for NSCLC市場の全体的な規模についての予測も含まれています。
本レポートは、世界のNSCLC用ターゲット薬剤BRAF阻害剤市場において、競合他社に対して優位に立ち、永続的な成功を収めるための効果的なツールであることを証明しています。本レポートに掲載されているすべての調査結果、データ、情報は、信頼できる情報源の助けを借りて検証、再検証されています。本レポートを執筆したアナリストは、世界のNSCLC向け標的薬剤BRAF阻害剤市場を詳細に調査するために、独自の業界最高水準の調査・分析手法を用いています。

世界のNSCLC用ターゲット薬BRAF阻害剤の範囲と市場規模
NSCLC用ターゲットドラッグBRAF阻害剤市場は、企業別、地域(国)別、タイプ別、アプリケーション別に分類されています。世界のNSCLC向け標的薬剤BRAF阻害剤市場のプレイヤー、ステークホルダー、その他の参加者は、本レポートを強力なリソースとして活用することで、優位に立つことができるでしょう。セグメント別分析では、2016年から2027年の期間で、タイプ別とアプリケーション別の収益と予測に焦点を当てています。

タイプ別セグメント
Dabrafenib(ダブラフェニブ
Trametinib(トラメチニブ
Lifirafenib
その他

用途別セグメント
NSCLCの扁平上皮癌(Squamous Cell Carcinoma of NSCLC
NSCLCの腺癌
大細胞癌(NSCLC

地域別
北アメリカ
米国
カナダ
ヨーロッパ
ドイツ
フランス
イギリス
イタリア
ロシア
北欧
その他のヨーロッパ諸国
アジア太平洋地域
中国
日本
韓国
東南アジア
インド
オーストラリア
その他のアジア諸国
ラテンアメリカ
メキシコ
ブラジル
その他のラテンアメリカ
中近東・アフリカ
トルコ
サウジアラビア
アラブ首長国連邦
その他の中東・アフリカ地域

会社別
BeiGene
ノバルティス


ページTOPに戻る


目次

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Targeted Drug BRAF Inhibitors for NSCLC Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Dabrafenib
1.2.3 Trametinib
1.2.4 Lifirafenib
1.2.5 Other
1.3 Market by Application
1.3.1 Global Targeted Drug BRAF Inhibitors for NSCLC Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Squamous Cell Carcinoma of NSCLC
1.3.3 Adenocarcinoma of NSCLC
1.3.4 Large Cell Carcinoma of NSCLC
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Targeted Drug BRAF Inhibitors for NSCLC Market Perspective (2016-2027)
2.2 Targeted Drug BRAF Inhibitors for NSCLC Growth Trends by Regions
2.2.1 Targeted Drug BRAF Inhibitors for NSCLC Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Targeted Drug BRAF Inhibitors for NSCLC Historic Market Share by Regions (2016-2021)
2.2.3 Targeted Drug BRAF Inhibitors for NSCLC Forecasted Market Size by Regions (2022-2027)
2.3 Targeted Drug BRAF Inhibitors for NSCLC Industry Dynamic
2.3.1 Targeted Drug BRAF Inhibitors for NSCLC Market Trends
2.3.2 Targeted Drug BRAF Inhibitors for NSCLC Market Drivers
2.3.3 Targeted Drug BRAF Inhibitors for NSCLC Market Challenges
2.3.4 Targeted Drug BRAF Inhibitors for NSCLC Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Targeted Drug BRAF Inhibitors for NSCLC Players by Revenue
3.1.1 Global Top Targeted Drug BRAF Inhibitors for NSCLC Players by Revenue (2016-2021)
3.1.2 Global Targeted Drug BRAF Inhibitors for NSCLC Revenue Market Share by Players (2016-2021)
3.2 Global Targeted Drug BRAF Inhibitors for NSCLC Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Targeted Drug BRAF Inhibitors for NSCLC Revenue
3.4 Global Targeted Drug BRAF Inhibitors for NSCLC Market Concentration Ratio
3.4.1 Global Targeted Drug BRAF Inhibitors for NSCLC Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Targeted Drug BRAF Inhibitors for NSCLC Revenue in 2020
3.5 Targeted Drug BRAF Inhibitors for NSCLC Key Players Head office and Area Served
3.6 Key Players Targeted Drug BRAF Inhibitors for NSCLC Product Solution and Service
3.7 Date of Enter into Targeted Drug BRAF Inhibitors for NSCLC Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Targeted Drug BRAF Inhibitors for NSCLC Breakdown Data by Type
4.1 Global Targeted Drug BRAF Inhibitors for NSCLC Historic Market Size by Type (2016-2021)
4.2 Global Targeted Drug BRAF Inhibitors for NSCLC Forecasted Market Size by Type (2022-2027)

5 Targeted Drug BRAF Inhibitors for NSCLC Breakdown Data by Application
5.1 Global Targeted Drug BRAF Inhibitors for NSCLC Historic Market Size by Application (2016-2021)
5.2 Global Targeted Drug BRAF Inhibitors for NSCLC Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Targeted Drug BRAF Inhibitors for NSCLC Market Size (2016-2027)
6.2 North America Targeted Drug BRAF Inhibitors for NSCLC Market Size by Type
6.2.1 North America Targeted Drug BRAF Inhibitors for NSCLC Market Size by Type (2016-2021)
6.2.2 North America Targeted Drug BRAF Inhibitors for NSCLC Market Size by Type (2022-2027)
6.2.3 North America Targeted Drug BRAF Inhibitors for NSCLC Market Size by Type (2016-2027)
6.3 North America Targeted Drug BRAF Inhibitors for NSCLC Market Size by Application
6.3.1 North America Targeted Drug BRAF Inhibitors for NSCLC Market Size by Application (2016-2021)
6.3.2 North America Targeted Drug BRAF Inhibitors for NSCLC Market Size by Application (2022-2027)
6.3.3 North America Targeted Drug BRAF Inhibitors for NSCLC Market Size by Application (2016-2027)
6.4 North America Targeted Drug BRAF Inhibitors for NSCLC Market Size by Country
6.4.1 North America Targeted Drug BRAF Inhibitors for NSCLC Market Size by Country (2016-2021)
6.4.2 North America Targeted Drug BRAF Inhibitors for NSCLC Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada

7 Europe
7.1 Europe Targeted Drug BRAF Inhibitors for NSCLC Market Size (2016-2027)
7.2 Europe Targeted Drug BRAF Inhibitors for NSCLC Market Size by Type
7.2.1 Europe Targeted Drug BRAF Inhibitors for NSCLC Market Size by Type (2016-2021)
7.2.2 Europe Targeted Drug BRAF Inhibitors for NSCLC Market Size by Type (2022-2027)
7.2.3 Europe Targeted Drug BRAF Inhibitors for NSCLC Market Size by Type (2016-2027)
7.3 Europe Targeted Drug BRAF Inhibitors for NSCLC Market Size by Application
7.3.1 Europe Targeted Drug BRAF Inhibitors for NSCLC Market Size by Application (2016-2021)
7.3.2 Europe Targeted Drug BRAF Inhibitors for NSCLC Market Size by Application (2022-2027)
7.3.3 Europe Targeted Drug BRAF Inhibitors for NSCLC Market Size by Application (2016-2027)
7.4 Europe Targeted Drug BRAF Inhibitors for NSCLC Market Size by Country
7.4.1 Europe Targeted Drug BRAF Inhibitors for NSCLC Market Size by Country (2016-2021)
7.4.2 Europe Targeted Drug BRAF Inhibitors for NSCLC Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Targeted Drug BRAF Inhibitors for NSCLC Market Size (2016-2027)
8.2 Asia-Pacific Targeted Drug BRAF Inhibitors for NSCLC Market Size by Type
8.2.1 Asia-Pacific Targeted Drug BRAF Inhibitors for NSCLC Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Targeted Drug BRAF Inhibitors for NSCLC Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Targeted Drug BRAF Inhibitors for NSCLC Market Size by Type (2016-2027)
8.3 Asia-Pacific Targeted Drug BRAF Inhibitors for NSCLC Market Size by Application
8.3.1 Asia-Pacific Targeted Drug BRAF Inhibitors for NSCLC Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Targeted Drug BRAF Inhibitors for NSCLC Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Targeted Drug BRAF Inhibitors for NSCLC Market Size by Application (2016-2027)
8.4 Asia-Pacific Targeted Drug BRAF Inhibitors for NSCLC Market Size by Region
8.4.1 Asia-Pacific Targeted Drug BRAF Inhibitors for NSCLC Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Targeted Drug BRAF Inhibitors for NSCLC Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Targeted Drug BRAF Inhibitors for NSCLC Market Size (2016-2027)
9.2 Latin America Targeted Drug BRAF Inhibitors for NSCLC Market Size by Type
9.2.1 Latin America Targeted Drug BRAF Inhibitors for NSCLC Market Size by Type (2016-2021)
9.2.2 Latin America Targeted Drug BRAF Inhibitors for NSCLC Market Size by Type (2022-2027)
9.2.3 Latin America Targeted Drug BRAF Inhibitors for NSCLC Market Size by Type (2016-2027)
9.3 Latin America Targeted Drug BRAF Inhibitors for NSCLC Market Size by Application
9.3.1 Latin America Targeted Drug BRAF Inhibitors for NSCLC Market Size by Application (2016-2021)
9.3.2 Latin America Targeted Drug BRAF Inhibitors for NSCLC Market Size by Application (2022-2027)
9.3.3 Latin America Targeted Drug BRAF Inhibitors for NSCLC Market Size by Application (2016-2027)
9.4 Latin America Targeted Drug BRAF Inhibitors for NSCLC Market Size by Country
9.4.1 Latin America Targeted Drug BRAF Inhibitors for NSCLC Market Size by Country (2016-2021)
9.4.2 Latin America Targeted Drug BRAF Inhibitors for NSCLC Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Targeted Drug BRAF Inhibitors for NSCLC Market Size (2016-2027)
10.2 Middle East & Africa Targeted Drug BRAF Inhibitors for NSCLC Market Size by Type
10.2.1 Middle East & Africa Targeted Drug BRAF Inhibitors for NSCLC Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Targeted Drug BRAF Inhibitors for NSCLC Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Targeted Drug BRAF Inhibitors for NSCLC Market Size by Type (2016-2027)
10.3 Middle East & Africa Targeted Drug BRAF Inhibitors for NSCLC Market Size by Application
10.3.1 Middle East & Africa Targeted Drug BRAF Inhibitors for NSCLC Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Targeted Drug BRAF Inhibitors for NSCLC Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Targeted Drug BRAF Inhibitors for NSCLC Market Size by Application (2016-2027)
10.4 Middle East & Africa Targeted Drug BRAF Inhibitors for NSCLC Market Size by Country
10.4.1 Middle East & Africa Targeted Drug BRAF Inhibitors for NSCLC Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Targeted Drug BRAF Inhibitors for NSCLC Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 BeiGene
11.1.1 BeiGene Company Details
11.1.2 BeiGene Business Overview
11.1.3 BeiGene Targeted Drug BRAF Inhibitors for NSCLC Introduction
11.1.4 BeiGene Revenue in Targeted Drug BRAF Inhibitors for NSCLC Business (2016-2021)
11.1.5 BeiGene Recent Development
11.2 Novartis
11.2.1 Novartis Company Details
11.2.2 Novartis Business Overview
11.2.3 Novartis Targeted Drug BRAF Inhibitors for NSCLC Introduction
11.2.4 Novartis Revenue in Targeted Drug BRAF Inhibitors for NSCLC Business (2016-2021)
11.2.5 Novartis Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

 

ページTOPに戻る


 

Summary

Market Analysis and Insights: Global Targeted Drug BRAF Inhibitors for NSCLC Market
The global Targeted Drug BRAF Inhibitors for NSCLC market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Targeted Drug BRAF Inhibitors for NSCLC market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Targeted Drug BRAF Inhibitors for NSCLC market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Targeted Drug BRAF Inhibitors for NSCLC market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Targeted Drug BRAF Inhibitors for NSCLC market.

Global Targeted Drug BRAF Inhibitors for NSCLC Scope and Market Size
Targeted Drug BRAF Inhibitors for NSCLC market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Targeted Drug BRAF Inhibitors for NSCLC market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Dabrafenib
Trametinib
Lifirafenib
Other

Segment by Application
Squamous Cell Carcinoma of NSCLC
Adenocarcinoma of NSCLC
Large Cell Carcinoma of NSCLC

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
BeiGene
Novartis



ページTOPに戻る


Table of Contents

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Targeted Drug BRAF Inhibitors for NSCLC Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Dabrafenib
1.2.3 Trametinib
1.2.4 Lifirafenib
1.2.5 Other
1.3 Market by Application
1.3.1 Global Targeted Drug BRAF Inhibitors for NSCLC Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Squamous Cell Carcinoma of NSCLC
1.3.3 Adenocarcinoma of NSCLC
1.3.4 Large Cell Carcinoma of NSCLC
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Targeted Drug BRAF Inhibitors for NSCLC Market Perspective (2016-2027)
2.2 Targeted Drug BRAF Inhibitors for NSCLC Growth Trends by Regions
2.2.1 Targeted Drug BRAF Inhibitors for NSCLC Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Targeted Drug BRAF Inhibitors for NSCLC Historic Market Share by Regions (2016-2021)
2.2.3 Targeted Drug BRAF Inhibitors for NSCLC Forecasted Market Size by Regions (2022-2027)
2.3 Targeted Drug BRAF Inhibitors for NSCLC Industry Dynamic
2.3.1 Targeted Drug BRAF Inhibitors for NSCLC Market Trends
2.3.2 Targeted Drug BRAF Inhibitors for NSCLC Market Drivers
2.3.3 Targeted Drug BRAF Inhibitors for NSCLC Market Challenges
2.3.4 Targeted Drug BRAF Inhibitors for NSCLC Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Targeted Drug BRAF Inhibitors for NSCLC Players by Revenue
3.1.1 Global Top Targeted Drug BRAF Inhibitors for NSCLC Players by Revenue (2016-2021)
3.1.2 Global Targeted Drug BRAF Inhibitors for NSCLC Revenue Market Share by Players (2016-2021)
3.2 Global Targeted Drug BRAF Inhibitors for NSCLC Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Targeted Drug BRAF Inhibitors for NSCLC Revenue
3.4 Global Targeted Drug BRAF Inhibitors for NSCLC Market Concentration Ratio
3.4.1 Global Targeted Drug BRAF Inhibitors for NSCLC Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Targeted Drug BRAF Inhibitors for NSCLC Revenue in 2020
3.5 Targeted Drug BRAF Inhibitors for NSCLC Key Players Head office and Area Served
3.6 Key Players Targeted Drug BRAF Inhibitors for NSCLC Product Solution and Service
3.7 Date of Enter into Targeted Drug BRAF Inhibitors for NSCLC Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Targeted Drug BRAF Inhibitors for NSCLC Breakdown Data by Type
4.1 Global Targeted Drug BRAF Inhibitors for NSCLC Historic Market Size by Type (2016-2021)
4.2 Global Targeted Drug BRAF Inhibitors for NSCLC Forecasted Market Size by Type (2022-2027)

5 Targeted Drug BRAF Inhibitors for NSCLC Breakdown Data by Application
5.1 Global Targeted Drug BRAF Inhibitors for NSCLC Historic Market Size by Application (2016-2021)
5.2 Global Targeted Drug BRAF Inhibitors for NSCLC Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Targeted Drug BRAF Inhibitors for NSCLC Market Size (2016-2027)
6.2 North America Targeted Drug BRAF Inhibitors for NSCLC Market Size by Type
6.2.1 North America Targeted Drug BRAF Inhibitors for NSCLC Market Size by Type (2016-2021)
6.2.2 North America Targeted Drug BRAF Inhibitors for NSCLC Market Size by Type (2022-2027)
6.2.3 North America Targeted Drug BRAF Inhibitors for NSCLC Market Size by Type (2016-2027)
6.3 North America Targeted Drug BRAF Inhibitors for NSCLC Market Size by Application
6.3.1 North America Targeted Drug BRAF Inhibitors for NSCLC Market Size by Application (2016-2021)
6.3.2 North America Targeted Drug BRAF Inhibitors for NSCLC Market Size by Application (2022-2027)
6.3.3 North America Targeted Drug BRAF Inhibitors for NSCLC Market Size by Application (2016-2027)
6.4 North America Targeted Drug BRAF Inhibitors for NSCLC Market Size by Country
6.4.1 North America Targeted Drug BRAF Inhibitors for NSCLC Market Size by Country (2016-2021)
6.4.2 North America Targeted Drug BRAF Inhibitors for NSCLC Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada

7 Europe
7.1 Europe Targeted Drug BRAF Inhibitors for NSCLC Market Size (2016-2027)
7.2 Europe Targeted Drug BRAF Inhibitors for NSCLC Market Size by Type
7.2.1 Europe Targeted Drug BRAF Inhibitors for NSCLC Market Size by Type (2016-2021)
7.2.2 Europe Targeted Drug BRAF Inhibitors for NSCLC Market Size by Type (2022-2027)
7.2.3 Europe Targeted Drug BRAF Inhibitors for NSCLC Market Size by Type (2016-2027)
7.3 Europe Targeted Drug BRAF Inhibitors for NSCLC Market Size by Application
7.3.1 Europe Targeted Drug BRAF Inhibitors for NSCLC Market Size by Application (2016-2021)
7.3.2 Europe Targeted Drug BRAF Inhibitors for NSCLC Market Size by Application (2022-2027)
7.3.3 Europe Targeted Drug BRAF Inhibitors for NSCLC Market Size by Application (2016-2027)
7.4 Europe Targeted Drug BRAF Inhibitors for NSCLC Market Size by Country
7.4.1 Europe Targeted Drug BRAF Inhibitors for NSCLC Market Size by Country (2016-2021)
7.4.2 Europe Targeted Drug BRAF Inhibitors for NSCLC Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Targeted Drug BRAF Inhibitors for NSCLC Market Size (2016-2027)
8.2 Asia-Pacific Targeted Drug BRAF Inhibitors for NSCLC Market Size by Type
8.2.1 Asia-Pacific Targeted Drug BRAF Inhibitors for NSCLC Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Targeted Drug BRAF Inhibitors for NSCLC Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Targeted Drug BRAF Inhibitors for NSCLC Market Size by Type (2016-2027)
8.3 Asia-Pacific Targeted Drug BRAF Inhibitors for NSCLC Market Size by Application
8.3.1 Asia-Pacific Targeted Drug BRAF Inhibitors for NSCLC Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Targeted Drug BRAF Inhibitors for NSCLC Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Targeted Drug BRAF Inhibitors for NSCLC Market Size by Application (2016-2027)
8.4 Asia-Pacific Targeted Drug BRAF Inhibitors for NSCLC Market Size by Region
8.4.1 Asia-Pacific Targeted Drug BRAF Inhibitors for NSCLC Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Targeted Drug BRAF Inhibitors for NSCLC Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Targeted Drug BRAF Inhibitors for NSCLC Market Size (2016-2027)
9.2 Latin America Targeted Drug BRAF Inhibitors for NSCLC Market Size by Type
9.2.1 Latin America Targeted Drug BRAF Inhibitors for NSCLC Market Size by Type (2016-2021)
9.2.2 Latin America Targeted Drug BRAF Inhibitors for NSCLC Market Size by Type (2022-2027)
9.2.3 Latin America Targeted Drug BRAF Inhibitors for NSCLC Market Size by Type (2016-2027)
9.3 Latin America Targeted Drug BRAF Inhibitors for NSCLC Market Size by Application
9.3.1 Latin America Targeted Drug BRAF Inhibitors for NSCLC Market Size by Application (2016-2021)
9.3.2 Latin America Targeted Drug BRAF Inhibitors for NSCLC Market Size by Application (2022-2027)
9.3.3 Latin America Targeted Drug BRAF Inhibitors for NSCLC Market Size by Application (2016-2027)
9.4 Latin America Targeted Drug BRAF Inhibitors for NSCLC Market Size by Country
9.4.1 Latin America Targeted Drug BRAF Inhibitors for NSCLC Market Size by Country (2016-2021)
9.4.2 Latin America Targeted Drug BRAF Inhibitors for NSCLC Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Targeted Drug BRAF Inhibitors for NSCLC Market Size (2016-2027)
10.2 Middle East & Africa Targeted Drug BRAF Inhibitors for NSCLC Market Size by Type
10.2.1 Middle East & Africa Targeted Drug BRAF Inhibitors for NSCLC Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Targeted Drug BRAF Inhibitors for NSCLC Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Targeted Drug BRAF Inhibitors for NSCLC Market Size by Type (2016-2027)
10.3 Middle East & Africa Targeted Drug BRAF Inhibitors for NSCLC Market Size by Application
10.3.1 Middle East & Africa Targeted Drug BRAF Inhibitors for NSCLC Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Targeted Drug BRAF Inhibitors for NSCLC Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Targeted Drug BRAF Inhibitors for NSCLC Market Size by Application (2016-2027)
10.4 Middle East & Africa Targeted Drug BRAF Inhibitors for NSCLC Market Size by Country
10.4.1 Middle East & Africa Targeted Drug BRAF Inhibitors for NSCLC Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Targeted Drug BRAF Inhibitors for NSCLC Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 BeiGene
11.1.1 BeiGene Company Details
11.1.2 BeiGene Business Overview
11.1.3 BeiGene Targeted Drug BRAF Inhibitors for NSCLC Introduction
11.1.4 BeiGene Revenue in Targeted Drug BRAF Inhibitors for NSCLC Business (2016-2021)
11.1.5 BeiGene Recent Development
11.2 Novartis
11.2.1 Novartis Company Details
11.2.2 Novartis Business Overview
11.2.3 Novartis Targeted Drug BRAF Inhibitors for NSCLC Introduction
11.2.4 Novartis Revenue in Targeted Drug BRAF Inhibitors for NSCLC Business (2016-2021)
11.2.5 Novartis Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

 

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同じKEY WORD(drug)の最新刊レポート


よくあるご質問


QYResearch社はどのような調査会社ですか?


QYリサーチ(QYResearch)は幅広い市場を対象に調査・レポート出版を行う、中国に本社をおく調査会社です。   QYResearchでは年間数百タイトルの調査レポートを出版しています。... もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
お客様よりデータリソース社へ(通常は円払い)の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

 

2024/11/14 10:27

156.77 円

166.04 円

201.95 円

ページTOPに戻る